Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Penserra Capital Management LLC

Penserra Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 394.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,735 shares of the medical instruments supplier's stock after buying an additional 2,979 shares during the quarter. Penserra Capital Management LLC's holdings in Becton, Dickinson and Company were worth $855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after purchasing an additional 184,288 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares during the period. Geode Capital Management LLC grew its holdings in Becton, Dickinson and Company by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after purchasing an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after purchasing an additional 810,345 shares during the period. Finally, First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 31.4% in the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after purchasing an additional 1,057,879 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX traded down $1.63 during trading on Friday, hitting $175.87. The company's stock had a trading volume of 2,428,716 shares, compared to its average volume of 2,078,243. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market cap of $50.41 billion, a PE ratio of 33.56, a P/E/G ratio of 1.34 and a beta of 0.25. The business's 50 day simple moving average is $172.33 and its 200-day simple moving average is $206.06.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $3.17 earnings per share. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.37%. Becton, Dickinson and Company's payout ratio is 79.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BDX shares. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.